Some of these drug treatments are in the advanced stages of clinical trials, including anti‐Aβ protein, anti‐tau, and anti‐inflammatory strategies, such as BAN2401, Aducanumab, and gantenerumab.[11, 12, 13] However, the drugs currently used in AD treatment have certain drawbacks, such as low bioavailability, blood–brain barrier penetration, and low half‐life. The gene discussed is MAPT; the disease is Alzheimer disease.